leisure time -WSS

leisure time

author：fashion 2025-09-11 06:21:29 - browse：12211

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Wikipedia

WSS

What will Novo Nordisk's VC do with its influx of cash?

European officials brace for rough respiratory virus season

Nobel honors Karikó and Weissman's enduring partnership

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

New oral drug delivery patch is modeled after octopus tentacles

European officials brace for rough respiratory virus season

knowledge

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

The EPA's new lead rule: How one expert crunched the numbers

Hepatitis C has a cure — but many Americans still lack access to it

The EPA's new lead rule: How one expert crunched the numbers

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Will the market for weight loss drugs really reach $100 billion?

In age of alternative facts, a scholarly course on calling out crap

Some top drug companies are starting to take action on climate

The cancer drug shortage isn’t new — and neither are the solutions

European officials brace for rough respiratory virus season

entertainment

With clinical trial data readouts, here's how to spot spin

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

30 years of 'Listening to Prozac'

Takeda, Janssen join wearable maker to measure scratching

Congress extends some pandemic preparedness programs

Fetal surgery at risk from Dobbs and new abortion restrictions

focus

leisure time

Wikipedia

hotspot